Principia Biopharma Inc (PRNB1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Martin Babler
Employees:
69
400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO, CA 94080
(650) 416-7700

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Data derived from most recent annual or quarterly report
Market Cap 3.323 Billion Shares Outstanding33.209 Million Avg 30-day Volume 872.827 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0 EBITDA0
Price to Book Value6.0076 Operating Margin0.0 Enterprise Value1.795 Billion
Current Ratio17.014 EPS Growth0 Quick Ratio14.578
1 Yr BETA 1.0296 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score37.032 Free Cash Flow to Firm -33.764 Million
View SEC Filings from PRNB1 instead.

View recent insider trading info

Funds Holding PRNB1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PRNB1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-09-28:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-06-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-03-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-01-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-12-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-10-15:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-10-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-08-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2019-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MACHADO PATRICK

    • Director
    No longer subject to file 2020-09-28 0

    COLOWICK ALAN

    • Director
    No longer subject to file 2020-09-28 0

    CHAI CHRISTOPHER Y CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2020-09-28 0

    BABLER MARTIN PRESIDENT, CEO

    • Officer
    • Director
    No longer subject to file 2020-09-28 0

    HARDIMAN ROY C. CHIEF BUSINESS OFFICER

    • Officer
    No longer subject to file 2020-09-28 0

    GEORGE SIMEON

    • Director
    No longer subject to file 2020-09-28 0

    TOMASELLO SHAWN

    • Director
    No longer subject to file 2020-09-28 0

    LIN SHAO-LEE

    • Director
    No longer subject to file 2020-09-28 0

    GOLDSTEIN DAVID M CHIEF SCIENTIFIC OFFICER

    • Officer
    No longer subject to file 2020-09-28 0

    WOLFF STEFANI CHIEF DEVELOPMENT OFFICER

    • Officer
    No longer subject to file 2020-09-28 0

    BECKER DANIEL J.

    • Director
    No longer subject to file 2020-09-28 0

    THOMAS DOLCA CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2020-09-28 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    0 2020-08-18 0

    GLAXOSMITHKLINE PLC

    • FORMER 10% OWNER
    2,982,855 2019-10-18 0

    NEW LEAF VENTURES II, L.P.

    NEW LEAF VENTURE ASSOCIATES II, L.P.

    NEW LEAF VENTURE MANAGEMENT II, L.L.C.

    NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

    NEW LEAF BPO ASSOCIATES II, L.P.

    NEW LEAF BPO MANAGEMENT II, L.L.C

    • 10% Owner
    No longer subject to file 2019-08-13 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP IV LLC

    • 10% Owner
    No longer subject to file 2019-05-21 0

    SMITHER JOHN W

    • Director
    0 2019-02-19 0

    SOFINNOVA VENTURE PARTNERS VIII, L.P.

    SOFINNOVA MANAGEMENT VIII, L.L.C.

    HEALY JAMES

    POWELL MICHAEL

    MEHRA ANAND

    • 10% Owner
    2,059,146 2018-09-18 0

    AKKARAJU SRINIVAS

    • Director
    383,480 2018-09-18 0

    GOURLAY STEVE CHIEF MEDICAL OFFICER

    • Officer
    107,857 2018-09-18 0

    BAKER BROS. ADVISORS LP

    BAKER BROS. ADVISORS (GP) LLC

    BAKER FELIX

    BAKER JULIAN

    • 10% Owner
    0 2018-09-13 0

    USMAN NASSIM

    • Director
    • 10% Owner
    0 2018-09-13 0

    AKKARAJU SRINIVAS

    AKKARAJU SRINIVAS

    • Director
    0 2018-09-13 0

    THOMPSON PETER A.

    • Director
    3,945 2018-09-13 0

    MORGENTHALER VENTURE PARTNERS IX LP

    MORGENTHALER MANAGEMENT PARTNERS IX, LLC

    • 10% Owner
    0 2018-09-13 0

    SHUSTER LEWIS

    • Director
    0 2018-09-13 0

    SHUSTER LEWIS

    SHUSTER LEWIS

    • Director
    0 2018-09-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund PRNB1 -668.0 shares, $-66806.68 2020-08-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund PRNB1 -91.0 shares, $-5403.58 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund PRNB1 -10.0 shares, $-593.8 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund PRNB1 -108.0 shares, $-6413.04 2020-03-31 N-PORT

    Elevate your investments